Form 4: Vaxart CMO Sells Shares for Tax Obligations

Vaxart's Chief Medical Officer, James F. Cummings, reported the disposition of 30,551 shares of common stock to cover tax liabilities related to RSU vesting.

Summary

• James F. Cummings, Chief Medical Officer of Vaxart, Inc., reported a transaction on March 24, 2026.
• 30,551 shares of Vaxart common stock were disposed of at a price of $0.694 per share.
• These shares were withheld by Vaxart to satisfy income tax withholding and remittance obligations in connection with the net settlement of Restricted Stock Units (RSUs) that vested on March 24, 2026.
• Following this transaction, Mr. Cummings directly beneficially owns 927,469 shares of Vaxart common stock.
• The total beneficial ownership includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine compliance filing for tax withholding on RSU vesting, which is a common occurrence for executives receiving equity compensation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as share dispositions for tax withholding upon RSU vesting, are common across all industries, particularly in biotechnology where executive compensation often includes significant equity components. These transactions are generally not indicative of management's sentiment towards the company's future prospects but rather a standard part of equity compensation plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related disposition, not a discretionary sale, reflecting the vesting of previously granted equity.
• Employees: Reflects standard equity compensation practices for executives.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares by an insider to cover tax obligations upon the vesting of Restricted Stock Units. Such transactions are common and generally do not reflect a change in the insider's confidence in the company's future or warrant a shift in investment strategy. Therefore, a 'hold' recommendation is appropriate as this specific filing provides no new material information to alter an existing investment thesis.

Keywords

Vaxart, VXRT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, James F. Cummings, Chief Medical Officer, Employee Stock Purchase Plan